Decision letter for "PROTAC Approaches against Drug-Resistant EGFRC797S/L858R/T790M Mutants: Biological Evaluation and SAR Studies (2020-2025)"

Publons reviews and discussion 2026

View at publisher

DOI: 10.1039/d5md01113b/v1/decision1

Cited by: 0

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Protein Degradation and Inhibitors HER2/EGFR in Cancer Research